Mutation in CNR1 gene and VEGF expression in esophageal cancer

Tumori

Volumn 95, Issue 1, 2009, Pages 68-75

  Bedoya, Fernando ^a   Meneu, Juan C ^b   Macías, María Isabel ^a   Moreno, Almudena ^b   Enríquez de Salamanca, Rafael ^a   Gonzalez, Enrique Moreno ^a   Vegh, Irene ^a,b  

^a Research Center   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cannabinoid receptor 1 gene; Esophageal cancer; Mutation; Vascular endothelial growth factor

Indexed keywords

CANNABINOID 1 RECEPTOR; VASCULOTROPIN;

ARTICLE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 63449103411     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500112     Document Type: Article

References (33)

1. Pertwee RG: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther, 4:129-180, 1997.
2. Gadzicki D, Müller-Vahl K, Stuhrmann M: A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes, 13: 321-323, 1999.
3. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Sem Oncol, 26: 2-8, 1998.
4. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR: Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol, 153: 287-294, 1998.
5. Wang LD, Chen H: Alteration of tumor suppressor gene p53-Rb system and human esophageal carcinogenesis. Shijie Huaren Xiaoluia Zazhi, 9: 367-371, 2002.
6. Guzman M: Cannabinoids: potential anticancer agents. Nat Rev Cancer, 3: 745-755, 2000.
7. Blázquez C, González-Feria 1, Alvarez L, Haro A, Llanos Casanova M, Guzmán M: Cannabinoids inhibit the vascular endothelial factor pathway in gliomas. Cancer Res, 64: 5617-5623, 2004.
8. Llanos Casanova M, Blázquez C, Martínez Palacio J, Villanueva C, Fernández-Acereño, Huffman JW, Jorcano JL, Guzman M: Inhibition of skin tumor growth and angiogénesis in vivo by activation of cannabinoid receptors. J Clin Invest, 111:43-50, 2003.
9. Guzman M, Sanchez C, Galve-Roperh I: Control of cell survival/death decision by cannabinoids. J Mol Med, 78: 613-625, 2001.
10. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141:118-126, 2000.
11. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V: Control by the endogenous cannabinoid system of ras oncogene-dependent tumor. FASEB J, 15: 2745-2747, 2001.
12. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev, 18: 4-25, 1997.
13. Inoue K, Ozeki Y, Suganuma T, Sugiera Y, Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer, 79: 206-213, 1997.
14. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res, 4: 2195-2200, 1998.
15. Möbius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jütting U, Siewert JR: Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. World J Surg, 28: 675-679 2004.
16. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist, 9: 2-10, 2004.
17. Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T, Chamaya K: Expression of hypoxia-inducible factor (HIF)-la is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer, 40: 1904-1912, 2004.
18. Bouck N: Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells, 2: 179-185, 1990.
19. World Health Organization: International classification of malignant tumours. Springer Verlag, Geneva, 1988.
20. th edition. Wiley-Liss, New York, 2002.
21. Sambrook J, Fritsch E, Manniatis T: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, New York, 1989.
22. Vegh I, De la Calle Santiuste, Colina F, Bor L, Bermejo C, Aragon A, Moran-Jimenez MJ, Gómez-Cámara A, Enríquez de Salamanca R, Moreno González E: Relationship between biomarker expression and allelic alteration in esophageal carcinoma. J Gastroenterol Hepathol, 22: 2303- 2309, 2007.
23. Vegh I, De-la Cruz J, Navarro S, Morales C, Colina P, Abad A, De-la-Calle A, Enríquez de Salamanca R, Moreno González E: Colorectal cancer relapse: Allelic alterations associated with tumor marker overexpression. Oncology, 65:146-151, 2003.
24. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di-Marzo V: A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J, 18: 1601-1608, 2004.
25. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L: The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine, 31: 138-141, 2007.
26. Russo P, Strazzullo P Cappuccio FR Tregouet DA, Lauria F, Loguercio M, Barba G, Versiero M, Siani A: Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab, 92: 2382-2386, 2007.
27. Mayer P, Höllt V: Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther, 91: 167-177, 2001.
28. Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse HE, Schmidt S, Höllt V: Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport, 8: 2547-2550, 1997.
29. Hixson JE, Almasy L, Cole S, Birnbaum S, Mitchell BD, Mahaney MC, Stern MP, MacCluer JW, Blangero J, Comuzzie AG: Normal variation in leptin levels is associated with polymorphisms in the proopiomelanocortin gene, POMC. J Clin Endocrinol Metab, 84: 3187-3191, 1999.
30. Chao HK, Hsiao KJ Su TS: A silent mutation induces exon skipping in the phenylalanine hydroxylase gene in phenylketonuria. Hum Genet, 108: 14-19, 2001.
31. Montera M, Piaggio F, Marchese C, Gismonti U, Stella A, Resta N, Varesco L, Guanti G, Mareni C: A silent mutation in exon 14 of the APC gene is associated with exon skipping in FAP family. J Med Genet, 38: 863-867, 2001.
32. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G, Wong J: Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res, 11:6190-6197, 2005.
33. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R: p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer, 89: 51-62, 2000.